Form 4: Theravance Biopharma Executive Brett A. Grimaud Reports Share Disposal for Tax Obligations

Brett A. Grimaud, SVP, General Counsel, and Secretary of Theravance Biopharma, Inc., reported disposing of 9,268 ordinary shares to cover tax obligations related to vesting restricted stock units on August 20, 2024.

Summary

• On August 20, 2024, Brett A. Grimaud, a Senior Vice President, General Counsel, and Secretary at Theravance Biopharma, Inc., disposed of 9,268 ordinary shares.
• The shares were withheld by the company to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
• The transaction price was $8.22 per share.
• Following the transaction, Grimaud directly owns 342,613 ordinary shares.
• The share withholding transaction was with the issuer and did not involve an open market transaction.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing relates to a routine transaction for tax purposes and doesn't indicate a change in the executive's overall confidence in the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities. This provides transparency to the market regarding insider transactions.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a standard procedure for covering tax obligations.

Key Dates